Zevra Therapeutics Appoints Global Medical Leader, Adrian
CELEBRATION, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics...
Source: globenewswire.com
Page 2 - Company Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Company Expanded Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Company Expanded Access Program Today - Breaking & Trending Today
RedHill Biopharma : and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola - Form 6-K -December 20, 2023 at 08:58 am EST
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...
Source: marketscreener.com
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received...
Source: prnewswire.com
RedHill Biopharma : Exercise of Existing Warrants Resulting in $4 Million Proceeds to the Company - Form 6-K -December 06, 2023 at 07:05 am EST
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C....
Source: marketscreener.com
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study.
Source: yahoo.com